WO2023180533 - ANTI-GAL3 ANTIBODIES AND COMPOSITIONS
National phase entry:
Publication Number
WO/2023/180533
Publication Date
28.09.2023
International Application No.
PCT/EP2023/057647
International Filing Date
24.03.2023
Title **
[English]
ANTI-GAL3 ANTIBODIES AND COMPOSITIONS
[French]
ANTICORPS ANTI-GAL3 ET COMPOSITIONS
Applicants **
LES LABORATOIRES SERVIER
Inventors
DE CEUNINCK, Frédéric
ORTEIGA-FERREIRA, Céline
GALLOU, Catherine
ROBIN, Gautier
Priority Data
22305372.9
25.03.2022
EP
22306186.2
04.08.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5812 | |
| EPO | Filing, Examination, Granting | 123482 | |
| Japan | Filing, Examination, Granting | 5038 | |
| South Korea | Filing, Examination, Granting | 9589 | |
| USA | Filing, Examination, Granting | 25590 |
Total:
169,511
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This invention relates to anti-Gal3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating Gal3 activity, e.g., fibrotic disease, inflammatory disease, autoimmune disease, 5 immune-mediated disorder, cancer, neurodegenerative disease, metabolic disease or infectious disease.[French]
La présente invention concerne des anticorps anti-Gal3 et des procédés d'utilisation de ceux-ci dans le traitement de maladies et d'états qui bénéficient de la modulation de l'activité Gal3, par exemple, d'une maladie fibrotique, d'une maladie inflammatoire, d'une maladie auto-immune, d'un trouble à médiation immunitaire, d'un cancer, d'une maladie neurodégénérative, d'une maladie métabolique ou d'une maladie infectieuse.